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ABSTRAK 
Perbandingan pembiusan separa spinal di an tara Ropivacaine O.So/o dan Bupivacaine 
O.So/o untuk pembedahan ortopedik. 
PENGENALAN 
Ropivacaine, ejen local anaesthetic bam yang berkongsi struktur dan fannakologi dengan 
bupivacaine, mempunyali kelebihan dari segi kadar toksik untuk jan tung yang minima serta 
keupayaan fungsi daya gerakan kembali ke tahap normal selepas pembiusan adalah lebih 
pantas. Ini adalah kerana ropivacaine mempunyai ciri S (-) enantiomer tulen. 
METODOLOGI 
Seramai 72 pesakit ASA grade 1-11 yang dijadualkan untuk pembedahan orthopedic anggota 
kaki, dibahagikan secara rawak kepada kumpulan yang menerima 15 mg ropivacaine 0.5% 
atau 15 mg bupivacaine 0.5% untuk pembiusan secara spinal. 
KEPUTUSAN 
Purata jangkamasa hilang daya rasa pada paras T12 adalah 4 minit (SD ±3.4) untuk 
kumpulan bupivacaine dan 5.1 minit (SD ±3.3) untuk kumpulan ropivacaine (P<0.207). 
Untuk menghalang daya rasa sehingga ke paras Tl 0 memerlukan 6.4 minit (SD ±3.3) bagi 
kumpulan bupivacaine dan 9.3 minit (SD ±5.2) bagi kumpulan ropivacaine (P<0.015). 
Sementara itu untuk menghalang daya rasa ke tahap T4, kumpulan bupivacaine mengambil 
masa 6.9 minit (SD ±3.7) manakala 15 minit (SD ±4.1) untuk kumpulan ropivacaine 
(P<O.OOI). Purata lama masa daya rasa hilang dari awal pembiusan diberi adalah 5.4 jam 
IX 
(SD ±I.2) untuk kurnpulan bupivacaine dan 6.5 jam (SD ±2.4) untuk kumpulan 
ropivacaine (P<0.02). Purata masa untuk daya pergerakan hilang mengikut "Modified 
Bromage Score" (MBS) adalah seperti berikut: MBS I - I.4 minit (SD ±0.8) bupivacaine, 
2.1 (SD ±I.5) ropivacaine (P<O.O I); MBS2 - I.6 minit (SD ±0.9) bupivacaine, ropivacaine 
3 minit (SD ±2.0) (P<0.001); MBS 3- 2.1 minit (SD ±1.1) bupivacaine, 3.6 minit (SD 
±1.8) ropivacaine (P<O.OOl). Masa yang diambil untuk daya pergerakan hilang dari 
permulaan pembiusan adalah 4.7 jam (SD ±1.1) untuk kumpulan bupivacaine dan 3.5 jam 
(SD ±1.4) untuk kumpulan ropivacaine (P<0.001). 
KESIMPULAN 
I5 mg ropivacaine 0.5% sesuai untuk menghalang daya rasa dan daya pergerakan di bawah 
paras TI2 dalamjangkamasa yang singkat serta menghindar. Rasa sakit untuk satu tempoh 
yang panjang samping membolehkan daya pergerakan kembali normal dalam tempoh yang 
singkat. 
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ABSTRACT 
A Comparison of Plain Ropivacaine 0.5% \Vith Plain Bupivacaine 0.5% in Spinal 
Anaesthesia for Orthopaedic Surgery. 
INTRODUCTION 
Bupivacaine is a popular local anaesthetic drug used for spinal anesthesia, it is relatively 
cardiotoxic and has a longer duration of motor blockade leading to longer discharge time, 
research for newer local anaesthetic with less cardiotoxicity and minimal motor blockade is 
aimed. Ropivacaine is a relatively new long-acting local anesthetic used in spinal 
anaesthesia, which is structurally and pharmacologically closely related to bupivacaine. 
However, unlike bupivacaine, which is synthesized as a racemic mixture, ropivacaine is 
synthesized as a pure S (-) enantiomer. This characteristic feature of the drug may 
contribute to its faster return of motor function than bupivacaine, and with lower risk of 
cardiotoxicity. 
METHODOLOGY 
A double blind randomized clinical trial on 72 ASA grade 1- II patients who were 
scheduled to undergo orthopedic surgery of the lower limb with duration of operation less 
than 3 hours were included in the study. These patients received an intrathecal injection of 
either: 15 mg of 0.5% plain ropivacaine (3 ml), or 15 mg of 0.5% plain bupivacaine (3 ml) 
for the above procedure. 
RESULTS 
The mean onset of sensory block at T12 dermatome was 4 minutes (SD ±3.4) 1n 
bupivacaine group and in ropivacaine group it was 5.1 minutes (SD ±3.3) (P<0.207). 
Xl 
Where as to reach Tl 0 in bupivacaine group was 6.4 minutes (SD ±3.3) and in ropivacaine 
group reached in 9.3 minutes (SD ±5.2) (P<O.Ol5). Regarding sensory block at T4, 20 
patients (55.5%) in bupivacaine group reached this level with mean onset of sensory block 
in 6.9 minutes (SD ±3.7). Where as only 4 patients (11 %) in ropivacaine group were able to 
reach the level of T4 in 15 minutes (SD ±4.08) (P<O.OOl). The duration of sensory block 
was assessed by the patient's first request for analgesia. In bupivacaine group the mean 
duration of time of sensory block was 5.4 hours (SD ±1.2) and in ropivacaine group it was 
6.5 hours (SD ±2.44) (P<0.02). The mean onset of motor block to reach Modified Bromage 
Score (MBS 1) in bupivacaine group was 1.4 minutes (SD ±0.8) and in ropivacaine group it 
was 2.1 minutes (SD ±1.5) (P<0.01). And to reach MBS2, in bupivacaine group and in 
ropivacaine group was 1.6 minutes (SD ±0.9) and 3.0 minutes (SD ±2.0) respectively 
(P<O.OOl). While to reach MBS3 bupivacaine group was 2.1 minutes (SD ±1.1) and in 
ropivacaine group it was 3.6 minutes (SD ±1.8) (P<O.OOI). In the bupivacaine group the 
mean duration of motor block was 4.7 hours (SD ±1.1) and in ropivacaine group was 3.5 
hours (SD ±1.4) (P<O.OOl). 
CONCLUSION 
Ropivacaine in a dose of 15 mg as 0.5% solution can be used with an acceptable onset of 
sensory and motor blockade with a longer duration of analgesia and early mobilization for 
lower limb orthopedic surgery of duration less than three hours and a level of lower than 
T12 dermatome. 
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CHAPTER ONE 
1. INTRODUCTION 
Bupivacaine is a popular drug for spinal anaesthesia, but because of its cardiotoxicity and 
longer duration of motor blockade leading to longer discharge time (Pavlin 1998), the 
laboratory research programme was aimed at identifying a local anesthetic with a similar 
clinical profile, but with less cardiotoxicity than bupivacaine. The research for alternatives 
to bupivacaine has concentrated on amide-linked agents. Ropivacaine and levobupicaine 
are two relatively new amide local anaesthetic agents that have been produced in order to 
address the issue ofbupivacaine cardiotoxicity (Whiteside JB et al. 2001). 
Ropivacaine is a relatively new long acting local anaesthetic, which is structurally and 
pharmacologically closely related to bupivacaine. However, unlike bupivacaine, which is 
synthesized as a racemic mixture, ropivacaine is synthesized as a pure S (-) enantiomer. It 
has 10-fold less lipid solubility than bupivacaine, which may decrease its accumulation in 
certain tissues, including myelinated A-alpha motor fibers. This characteristic may 
contribute to its faster return of motor function than bupivacaine. Clinical pharmacological 
studies also showed that ropivacaine has a lower risk of cardiotoxicity. These two 
advantages have currently made the use of ropivacaine more popular for epidural 
anaesthesia especially in postoperative analgesia and in the management of labor pain 
(Levin A. 1998). 
I 
The use of ropivacaine in spinal anaesthesia is relatively new and limited studies have been 
done. Because of its less dense motor blockade, most of the studies first focused more on 
its possible benefits in ambulatory surgery (Gautier Ph.E et al. 1999), cesarean delivery 
(Kim SK et al. 2002), and then they started to study its effect on other type of procedures 
like orthopedic and general surgery in its two forms; hyperbaric (Whiteside J .B et al. 2003) 
or plain (isobaric) (Me Namee D.A et al. 2002). 
We would like to study the use of plain ropivacaine in spinal anaesthesia of the lower limb 
orthopedic surgery and compare its characteristics with that of plain bupivacaine in term of 
onset of both sensory and motor block as well as duration of block with the maximum 
cephalad spread, quality of analgesia and muscle relaxation and its safety in use. 
2 
2. OBJECTIVES 
The main objective of this study is to compare plain ropivacaine in a dose of 15 mg as 0.5% 
solution with plain bupivacaine in a dose of 15 mg as 0.5% solution in orthopedic surgery 
for lower limb of duration less than three hours. 
1.1. To compare the onset and duration of sensory block to T1 0 with plain 
ropivacaine 15 mg as 5% solution and plain bupivacaine 15 mg as 0.5% solution. 
1.2. To compare the onset and duration of motor block using plain ropivacaine and 
plain bupivacaine with the above dosage. 
1.3. To compare the maximum block spread of plain ropivacaine with plain bupivacaine 
with the above dosage 
1.4. To assess the quality of analgesia with the use of plain ropivacaine and plain 
bupivacaine with the above dosage 
1.5. To assess muscle relaxation induced by plain ropivacaine and plain bupivacaine 
using the above dosage 
1.6. To assess intraoperative and postoperative complications of plain ropivacaine and 
plain bupivacaine using the above dosage 
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CHAPTER TWO 
LITRATURE REVIEW 
2.1 PHARMACOLOGY OF LOCAL ANAESTHETICS 
The first local anaesthetic to be discovered was cocaine, an alkaloid form of leaves of the 
plant Erythroxylon coca, found in the highlands of Peru. Pure alkaloid was first isolated by 
Neimann. In 1880, von Anrep was the frrst to describe the sensory anaesthetic action of 
subcutaneous injection and recommended its use as such, however this was not acted upon. 
In 1884, Carl Koller made the first documented use of local anaesthesia for surgery, when 
he introduced its topical use into ophthalmology. In the same year, Hall introduced its use 
into dentistry. In the following year, Halsted demonstrated its efficacy in blocking 
conduction in nerve trunks (William et al. 1996). Coming, in 1885, induced spinal 
anaesthesia in dogs, and in 1895, Coming injected cocaine 110 mg at the level Tll/T12 to 
treat habitual masturbation. In 1898, Bier performed the first spinal anesthesia, and 
described the first postdural puncture headache {Turnbull D.K et al. 2003). However, the 
search for chemical substitutes for cocaine began in 1892, with the work of Einhorn and 
colleagues and procaine resulted in 1905 (Brown D.L et al. 2000). Lofgren synthesized 
lidocaine in 1943, and since then, with the exception of chloroprocaine, all new local 
anaesthetics introduced into clinical practice have been amino-amides (William et al. 
1996). So for utilization of these agents, the safe and effective use depends on the 
understanding of the pharmacokinetics and pharmacodynamics of the various local 
anaesthetics available today. 
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2.1.1 MECHANISM OF ACTION 
The generation and propagation of impulses in nerve axons to carry afferent (sensory) and 
efferent (motor, sympathetic) infonnation requires the flow of specific ionic currents 
through charmels in the plasma membrane. These channels open and close depending on 
the electrical potential of the cell membrane. The major determinant of the depolarization 
of nerve fibers is dependent on the specific influx of sodium ions through sodium channels 
in nerve cell axons. Local anaesthetic agents reversibly bind to and block the sodium 
channels, thereby preventing the initiation or propagation of the electrical impulses required 
for nerve conduction (Stoelting RV. 1999). 
It now appears that although the uncharged f01m of a local ar1aesthetic is more likely to 
cross into the cell membrane, either form may bind to the sodium channel. Sodium 
channels exist in activated-open, inactivated-closed, and rested-closed states during various 
phases of the action potential. In the resting nerve membrane, sodium channels are 
distributed in equilibrium between the rested-closed and inactivated-closed states. By 
selectively binding to sodium channels in inactivated-closed states, local anesthetic 
molecules stabilize these channels in this configuration and prevent their change to the 
rested-closed and activated-open states in response to nerve impulses. Sodium channels in 
the inactivated-closed state are not permeable to sodium, and thus conduction of nerve 
impulses in the form of propagated action potentials cannot occur. It is speculated that local 
anesthetics bind to specific sites located on the inner portion of sodium channels (internal 
gate) as well as obstructing sodium channels ncnr their cxtomn1 openings to ntaintait1 these 
channels in inactivated-closed states (Butterworth & Strichartz. 1990). 
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Sodium ion channels tend to recover from local anaesthetic-induced conduction blockade 
between action potentials and to develop additional conduction blockade each time sodium 
channels open during an action potential (frequency-dependant blockade). Hence, local 
anaesthetic molecules can gain access to receptors only when sodium channels are in 
activated-open states. For this reason, selective conduction blockade of nerve fibers by 
local anaesthetics may be related to the nerve's characteristic frequencies of activity as well 
as to anatomical properties. So sensory fibers, especially pain fibers, have a high firing rate 
and relatively long action potential duration than motor fibers, and thus are more sensitive 
to low concentration of local anaesthetics. Frequency- and voltage-dependence is also the 
mechanism of anti-arrhythmic effects of local anaesthetics on cardiac cells (Bromage et al. 
1974). 
Local anaesthetics have differential conduction blockade properties in which it prefers to 
block small nerve fibers; this is because distance of passive propagation of impulses in the 
small fibers is shorter, in general, small unmyelinated C-fibers (pain) and small myelinated 
Ao-fibers (pain and temperature) are blocked before larger myelinated Aa., A(3 and Ay 
fibers (postural, touch, pressure and motor signals), also in nerve bundles, fibers that are 
located circumferentially are affected first by local anaesthetics. So in the large nerve 
trunks, motor nerves are usually located circumferentially and may be affected before the 
sensory fibers. In the extremities, proximal sensory fibers are located more 
circumferentially than distal sensory fibers. Thus, loss of sense may spread from proximal 
to distal part of the limb. Local anaesthetics action is affected by the pH of the application 
site. It also is uncertain whether local anaesthetics cross into the cell through the cell 
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membrane or actually through the sodium channel, either way, the local anaesthetic initiates 
block of the channel by binding to the receptor inside the cell (William et al. 1996). 
2.1.2 CLASSIFICATION 
Local anaesthetics are commonly classified by the duration of their clinical actions. 
Structurally, based on the linkage between the aromatic portion and the amine portion of 
the compound, they can be classified as either esters or amides. The various local 
anaesthetic agents differ in terms of their potency, onset, and duration of action, depending 
in general on their physico-chemical properties as outlined below (Stoelting RV. 1999). 
The correlation between the physical properties and biologic properties are especially true 
for in vitro compared with in vivo nerve models. Recently, with the introduction of 
ropivacaine, chirality's has become yet another way to describe local anesthetics. A chiral 
carbon is one in which the four bonding atoms (or groups of atoms) are all different. This 
leads to the potential for that molecule to exist in two different three-dimensional mirror-
image configurations: the S (sinister, 1, levo, or left) or R (rectus, d, dextro, or right) 
isomers. Each stereoisomer has different physicochemical properties that potentially can be 
exploited for its unique pharmacological properties (Whiteside JB et al. 2001 ). 
Ropivacaine became the first synthetic local anaesthetic marketed that exists only as the S 
isomeric formulation and although all local anesthetics with the exception of Lignocaine 
potentially can be formulated as a pure isomer, all of them currently are racemic mixtures 
(Whiteside JB et al. 2001 ). 
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The potential advantages of having pure isomers are that perhaps a larger degree of toxicity 
or potency is due just to one of the isomers and the favorable one can be sought. This 
certainly appears to be true for ropivacaine where the R-enantiomer is three times more 
cardiotoxic than the S-enantiomer. The S-isomer of bupivacaine is being studied currently 
because of its more favorable side-effect profile compared with the R-isomer formulation. 
Results of this study could potentially lead to a new bupivacaine with all the desirable 
properties that minimizes the side-effects (Moller R & Cavino BG. 1990). 
2.1.2, (a). Esters 
Cocaine as described above was the first local anaesthetic and is also an ester. Albert 
Niemann, who noted the passionate chewing of the Coca leaves by the native Indians, 
discovered it in the 1850s. The first chemically synthesized ester was procaine. Procaine is 
still used for local infiltration, and although many other ester local anaesthetics have been 
synthesised as chloroprocaine, and tetracaine remain in clinical use (William et al. 1996). 
Ester linkage is relatively unstable, as a result ester local anaesthetics have a shorter shelf-
life and are sensitive to high temperatures. Esters are rapidly hydrolyzed having the half life 
of 1-3 minutes in plasma by the cholinesterase enzymes (plasma pseudocholinesterases and 
red blood cell esterase), with para-amino benzoic acid being one of the primary 
metabolites. Para-amino benzoic acid (as in lotion) is probably responsible for the majority 
of allergic reactions reported in a small number of patients who use ester-type drugs 
(Stoelting RV. 1999). 
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2.1.2, (b). Ami des 
Dibucaine was the first amide-type local anaesthetic synthesized, but its clinical use was 
limited secondary to its toxicity. Dibucaine is now used only for the diagnosis of 
cholinesterase deficiency and for quizzing residents and medical students. Lidocaine was 
introduced in 1943. It was the first amide class of local anaesthetic used widely in clinical 
practice. The other amide in order of synthesis is mepivacaine, prilocaine, bupivacaine, 
etidocaine, ropivacaine and levobupivacaine. The amides are extremely stable compounds 
and have long shelf-lives. They undergo degradation in the liver with plasma half-lives 
between 2 and 3 hours and allergic reactions to these compounds are rare. It is important 
that there is no cross-reactivity to allergies between esters and amides (Whiteside JB et al. 
2001). 
2.1.3. BUPIV A CAINE 
Bupivacaine is classified as an amide local anaesthetic, which used as a local anaesthetic, 
presented as a clear, colorless solution containing 0.25%, 0.5%, and 0.75% ofbupivacaine 
hydrochloride. The 0.25% and 0.5% solutions are available combined with 1: 200,000 
adrenaline. A 0.5% (heavy') solution containing 80 mg/ml of glucose is also available. 
2.1.3, (a). Pharmacokinetics 
Absorption of bupivacaine is similar to lignocaine but the addition of adrenaline does not 
prolong the duration of action of bupivacaine. Regarding distribution, it is 95% protein-
bound in the plasma; volume of distribution is 73 liters. 
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Metabolism occurs in the liver by N-dealkylation, primarily to pipcolyl oxylidine. Some 
5% of the dose is excreted in the urine as pipcolyl-oxylidine; 6% is excreted unchanged. 
The clearance is 0.47 Umin and the elimination half-life is 210 minutes. The drug can be 
administered by infiltration, intrathecally, epidurally and for major nerve blockade, 0.125-
0.25% with or without adrenaline may be used for infiltration analgesia and the onset of 
action is reasonably rapid, and the duration of action is 240 minutes ( 480 minutes with 
adrenaline). The onset of action for peripheral nerve block is about 20 minutes. 0.5% 
bupivacaine is used for surgical anaesthesia and when extra volume is needed, a more 
dilute (0.375%) may be used. The upper limit of safe dosage in the adults is 2-mg/kg body 
weights (Stoelting RV. 1999). 
2.1.3, (b). Pharmacodynamics 
Bupivacaine causes reversible peripheral neural blockade. Bupivacaine diffuse in their 
uncharged base form through neural sheaths and the axonal membrane to the internal 
surface of the cell membrane's sodium channels; where they combine with hydrogen ions 
to form a cationic species which enter the internal opening of the sodium ion channel and 
combines with a receptor. This produces blockade of the sodium ion channel, thereby 
decreasing sodium ion conductance and preventing depolarization of the cell membrane. In 
general, the actions are similar to lignocaine but it is markedly cardiotoxic, binds 
specifically to myocardial proteins. R-bupivacaine is also more arrhythmogenic, and slows 
ventricular conduction 4.6 times as much as S-bupivacaine. The decrease in cardiotoxicity 
due to S-bupivacaine's steroselectivity is the subject of a recent review. Given in toxic 
doses, it decreases myocardial contractility and the peripheral vascular resistance producing 
hypotension and possibly cardiovascular collapse (Stoelting RV. 1999). 
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2.1.3, (c). Contraindications and precautions 
Hypersensitivity reactions to bupivacaine may occur but are extremely rare. Caution should 
be taken in patients with fixed cardiac output state and shunts during performance of central 
neural axis blockade. Allergy to amide local anaesthetic is extremely rare (Stoelting RV. 
1999). 
2.1.3, (d). Adverse effects and side effects 
Side-effects are similar to lignocaine, such as convulsion, dizziness, perioral numbness, 
tinnitus and neurotoxic (neuritis), conduction blockade, arrhythmias, depression of 
myocardial contractility and hypotension but it is more cardiotoxic than lidocaine (Stoelting 
RV. 1999). 
2.1.4 ROPIV A CAINE 
Ropivacaine is the new long-acting amino-amide local anaesthetic combines the anaesthetic 
potency and long duration of action of bupivacaine with a toxicity profile intermediate 
between bupivacaine and lidocaine. It is presented as clear solution of 2%, 5%, 7.5% and 
10%. Ropivacaine is manufactured as the pure S-enantiomer in order to take advantage of 
the decreased cardiotoxicity (Whiteside JB et al. 2001 ). 
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2.1.4, (a). Pharmacokinetics 
Ropivacaine has a chiral center and is the pure S- (-)-enantiomer. Ropivacaine has a pKa of 
8.1. The metabolites have a pharmacological activity that is less than that of ropivacaine. 
The plasma concentration of ropivacaine depends upon the dose, the routes of 
administration and the vascularity of the injection site, metabolism in the liver by aromatic 
hydroxylation and N-dealkylation (Stoelting RV. 1999). About 3% of the metabolites are 
excreted in the urine. Ropivacaine has total plasma clearance of 440 ml/min, an unbound 
plasma clearance of 44 L/min, a renal clearance of 1 L/min, a volume of distribution at 
steady state of 41 liters and an elemination half-life of 108 minute after IV administration 
(Stoelting RV. 1999). 
2.1.4, (b). Pharmacodynamics 
Ropivacaine is the first long-acting, amide-type local anaesthetic with both anaesthetic and 
analgesic effects. At high doses it produces surgical anaesthesia, while at lower doses it 
produces sensory block with limited and non-progressive motor block. Onset and duration 
of the local anaesthetic effect of ropivacaine depends on the dose and site of administration, 
while the presence of a vasoconstrictor has little, if any influence. Ropivacaine, like other 
local anaesthetic, causes reversible blockade and similar affects on other excitable 
membranes e.g. brain and myocardium, but with lower cardiac toxicity compared to 
bupivacaine (Whiteside JB et al. 2001 ). 
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2.1.4, (c). Contraindications and precautions 
Caution should be taken in patients with fixed cardiac output states and shunts during 
performance of central neural axis blockade. Allergy to amide local anaesthetics is 
extremely rare (Stoelting RV. 1999). 
2.1.4, (d). Adverse effects and side effects 
The adverse reactions of ropivacaine are similar to those of bupivacaine as neurotoxicity, 
hypotension, bradycardia and urinary retention. The needle puncture may cause spinal 
haematoma, headache or may aid in introducing microorganisms as meningitis and abscess 
formation but with less incidence of cardiac toxicity than bupivacaine (Stoelting R V. 
1999). 
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2.2 SPINAL ANESTHESIA 
2.2.1. HISTORY 
In 1761, Colugno described the presence of a collection of water around the brain and 
inside the spinal column. In 1825, Magendie was credited with appreciating that this fluid 
circulated around the brain and the spinal column. By 1811, Zophar Jayne of Illinois had 
designed a syringe attached to a small, sharp, and hollow beak with an opening on the side 
near the tip. Subsequently, in 1853, Daniel Ferguson developed a syringe and hollow 
platinum trochar with an oblique opening on one side encased in outer tubing. Also with an 
oblique opening, Wood was credited for developing the first hollow hypodermic needle in 
1853 (William et al. 1996). 
The first local anaesthetic to be discovered was cocaine, an alkaloid form of leaves of the 
plant Erythroxylon coca, found in the highlands of Peru. So the history of the development 
of the spinal needle tip is one of trial and error, misattribution and unsolved problems. 
From the early hollow needles (1853), through the cutting bevel design (1900-1927-1993), 
to the current pencil-point needles (1951-1987-1996), the same initial problems are still 
evident today, albeit less commonly: postdural headaches, failed blocks and neurological 
damage (Calthorpe N et al. 2004). In 1880 von Anrep, was the first to describe the sensory 
anaesthetic action of subcutaneous injection and recommended its use as such, however this 
was not acted upon. And Carl Koller made the first documented use of local anaesthesia for 
surgery on 1884, when he introduced its topical use into ophthalmology. In the same year 
Hall introduced its use into dentistry (William et al. 1996). 
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Jolm Leonard Coming in 1885 produced spinal anaesthesia in dogs. In 1895 same Coming 
inject cocaine 110 mg at level Tll/T12 to treat habitual masturbation. Bier in 1898 
performed the first spinal anaesthesia, and he also described the first postdural puncture 
headache (Turnbull DK et al. 2003). So the search for chemical substitutes for cocaine 
began in 1892, with the work of Einhorn and colleagues. The result of the work is procaine 
in 1905 (Brown DL et al. 2000). Lofgren synthesized lidocaine in 1943 and since then, with 
the exception of chloroprocaine, all new local anesthetics introduced into clinical practice 
have been amino-amides. 
2.2.2. ANATOMY OF SPINAL CANAL 
The spinal canal is occupied by the spinal cord, which begins at the level of the foramen 
magnum and extends to the first or second lumbar vertebrae. It is continuous with the 
medulla oblongata above and ends below as the conus medullaris, from which the cauda 
equina (collection of segmental nerve fibers) and the filum terminale continue to the 
coccyx. At birth, the spina 1 cord ends at the third 1 urn bar vertebrae before rising to the 
more cephalic adult level. The cauda equina is suspended in spinal fluid allowing sufficient 
mobility to deviate from spinal needle tip, which enters the subarachnoid space. The spinal 
cord could be pierced by a needle that enters the spinal canal at level higher than L 1, this 
leads to greater popularity of the lumbar approach to neuraxial blockade. 
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As the tip of the needle enters the spinal canal and approaches the spinal cord or cauda 
equina, the following structures are sequentially encountered: the epidural space, the dura 
mater, the subdural space, the arachnoid mater and the subarachnoid space containing 
cerebrospinal fluid and spinal cord (the spinal cord is covered by the pia mater). First, the 
needle enters the epidural space. The posterior epidural space is located between the dura 
mater anteriorly, the ligamentum flavum posteriolaterally, and the connective tissue of the 
laminea of the vertebrae laterally. The thin narrow anterior epidural space is situated 
between the posterior longitudinal ligament and the anterior spinal dura. 
The epidural space extends from the base of the skull to the sacrococcygeal ligament of the 
sacral hiatus. It is filled with fatty tissue, loose connective tissue, lymphatics, arteries, a 
rich venous plexus and segmental nerve roots traversing the lateral boundaries. After 
penetration into and through the posterior epidural space the needle tip next encounters the 
three protective coverings of the spinal cord and cauda equina. 
The outermost meningeal layer, the dura mater is compromised of longitudinally organized 
fibers that extend down the vertebral column as a fibroelastic tube and terminate at the 
inferior border of S2. For subarachnoid placement of local anaesthetics, the dura mater 
provides the characteristic "pop" which usually indicates that the subarachnoid space has 
been entered. Between the dura and arachnoid mater, immediately subdurally, there is a 
potential space that contains lymph and capillaries. In rare cases (0.1% to 0.2%) the needle 
tip and deposition of drugs may open this subdural space. 
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This may result in either a total spinal when epidural doses of drugs are administered or 
may be one of the potential causes of a failed spinal. This potential cavity extends to the 
nerve roots and ganglia with communication to the cranial cavity but once again, has no 
direct accessibility to the cerebral spinal fluid. Directly adjacent to the dura mater which is 
the arachnoid mater, a nonvascular connective tissue covering, is the middle meningeal 
membrane. With the dura mater, this meningeal layer also extends to the inferior border of 
the S2 vertebra. 
After passing through the arachnoid mater, the needle tip enters the subarachnoid space. 
This space contains the cerebrospinal fluid and is confined to the area between the pia and 
arachnoid mater. The pia mater is a fragile vascular membrane, closely attached to the 
spinal cord, the cauda equina and the spinal nerve roots. The spinal cord and spinal nerve 
roots are bathed in cerebrospinal fluid. As the spinal nerve roots penetrate beyond spinal 
dura and enter the epidural space, they retain all three meningeal layers. 
The subarachnoid space continues along both nerve roots (dorsal and ventral), ending at the 
dorsal root ganglia. Deeper penetration of the needle tip at the level of the cauda equine 
disperses the segmental nerves, which are covered by pia mater and leaves the 
subarachnoid space to enter into the anterior dura. At the spinal cord level, deeper 
penetration of the needle tip will encounter the pia mater before injuring the spinal cord. 
17 
2.2.3 DRUGS USED 
The choice of local anaesthetic to be used for intrathecal anaesthesia is usually based on the 
expected duration of surgery and need for early patient discharge. Because of changes in 
health care system organization, a significant increase in the number of surgical procedures 
performed on an out patient basis and intrathecal anaesthesia have also become regular and 
very popular for day-case procedures. 
2.2.3 (a). Short Acting Agents 
Lidocaine both as plain and heavy solutions in doses ranging from 50 to 100 mg is widely 
used for surgical procedures that last up to one hour. For shorter procedures the dose can he 
reduced to 40 mg, which provides an adequate surgical block with times for complete 
regression of spinal block of approximately 2 hours, meaning that the patient may be 
discharged from hospital 3 hours after intrathecal injection of doses of spinal lidocaine as 
low as 20 mg has been described for outpatient procedures, with high patient satisfaction 
and very rapid recovery and discharge, but only with the addition of small doses of fentanyl 
(Ben-David Bet al. 2001). 
Nonetheless, despite its broad use and lengthy history, the overwhelming evidence of 
transient neurological symptoms associated with spinal lidocaine raised concerns regarding 
its use, especially for day-case procedures (Freedman JM et al. 1998). 
Mepivacaine is another amide local anaesthetic with a clinical profile similar to that of 
lidocaine; however, it is also associated with a similarly high incidence of transient 
neurologic symptoms (Hiller A et al. 1997). 
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Procaine and prilocaine could theoretically be good alternatives to lidocaine for short-
lasting spinal anaesthesia, but they are not extensively available for intrathecal 
administration around the world (Liu SS et al. 2001) In comparison with 100 mg lidocaine 
5%, the same dose of procaine 10% provides a similar onset time, shorter resolution of 
nerve block, and lower incidence of transient neurological symptoms (Le Truong HH et al. 
2001). 
However, spinal procaine has also been reported to be associated with a higher failure rate 
and higher incidence of nausea as compared to lidocaine, resulting in delayed discharge 
times. Prilocaine used at the same dose as lidocaine provides a similar clinical profile, with 
the advantage of a lower incidence of transient neurological symptoms (Hampl KF et al. 
1998). 
2.2.3 (b). Long-Acting Agents 
Long-acting agents, such as bupivacaine with doses ranging between 10 and 20 mg of 
either plain or hyperbaric solutions and tetracaine with doses ranging between 8 and 16 mg 
of either plain or hyperbaric solutions are extensively used to provide intrathecal 
anaesthesia for surgical procedures that last up to 2-2.5 hours (Brown DL et al. 2000). The 
use of long-acting agents is associated with a lower risk for transient neurological 
dysfunction (Freedman JM et al. 1998). With increasing concerns regarding the 
development of neurological dysfunction after spinal lidocaine, the use of small doses of 
1 ong-acting agents to provide reliable spinal anaesthesia for short procedures has been 
investigated (Liu SS et al. 1996). 
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Bupivacaine, 5-8 mg (used as plain hypobaric or hyperbaric solutions) has been 
demonstrated to provide reliable spinal anaesthesia for out-patients, with recovery times 
comparable to those with 40-60 mg lidocaine (Pittoni G et al. 1995). Because it has been 
demonstrated that most of the toxic effects of bupivacaine are related to the D-enantiomer, 
the pharmaceutical research has recently focused on pure S-enantiomers. Two new long-
acting local anaesthetics have been developed ropivacaine and levobupivacaine (Whiteside 
JB et al. 2001 ). 
The efficacy and safety of intrathecal administration of both plain and hyperbaric solutions 
of ropivacaine have been evaluated in different clinical settings, including orthopedic, 
urologic surgery, cesarean sections and labor pain (Chung, C. J. et al. 2001). As for other 
agents, the use of hyperbaric solutions results in a faster onset and higher maximum 
sensory level, with shorter duration of nerve block (Khaw, K. S. et al. 2002). 
Ropivacaine is also 40--60% less potent than bupivacaine, Because of its lower 
lipophilicity (Polley LS et al. 1999). In a study conducted in volunteers, McDonald et al. 
1999 demonstrated that ropivacaine is associated with a shorter recovery time than is 
bupivacaine (when the two agents are used at similar doses). Thus, the use of small doses 
of ropivacaine could potentially confer some advantages over bupivacaine for outpatient 
procedures (Gautier Petal. 1999). Gautier compared the use of 8 mg ropivacaine with 8 
mg bupivacaine for outpatient knee arthroscopy and demonstrated that ropivacaine allows 
for earlier recovery of motor function and discharge than does the same dose of 
bupivacaine (Gautier P et al. 1999). 
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2.2.3 (c). Additives 
Several drugs other than local anaesthetics can be injected into the subarachnoid space, 
either alone or more frequently in addition to local anaesthetic solutions. There are two 
primary reasons for using additives with spinal local anaesthetics; first is to improve the 
quality and duration of spinal block and to minimize the dose of local anaesthetic injected, 
secondly to reduce the severity cardiac toxicity and to improve its clinical profile. 
• Epinephrine 
Epinephrine in a dose (0.1-0.2 mg) is widely used in addition to local anaesthetic both to 
minimize the systemic absorption of local anaesthetic and to prolong the duration of spinal 
block. However the addition of a potent vasoconstrictor may lead to transient neurological 
symptoms (Hashimoto et al. 2001 ). 
• Opioids 
Several reports have shown beneficial effect of adding a small dose of opioids such as 
fentanyl, sufentanil, and morphine to intrathecal local anaesthetic solutions on the 
prolongation of the duration of analgesia. The pain pathway is interrupted by two distinct 
mechanisms. The opioids inhibit pain transmission in the dorsal hom, and the local 
anaesthetic blocks the conduction in the nerve root and spinal cord (Bernadette Th et al. 
1998). Adding 10-20 Jlg fentanyl, 1-10 Jlg sufentanil, or 0.1-0.2 mg morphine to either 
bupivacaine or lidocaine provides adequate intraoperative surgical block for lower limb or 
laparoscopic gynecologic outpatient procedures with very short times to discharge (Ben-
David B et al. 2000). 
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Because of its hydrophilicity, morphine has increased potential for rostral migration in the 
cerebrospinal fluid possibly leading to delayed respiratory depression. Lipophilic opioids 
such as fentanyl and sufentanil, has a faster onset of action and little risk for delayed 
respiratory depression (Hamber EA et al. 1999). 
• Clonidine 
Clonidine is a selective a.2 adrenergic agonist and given intrathecally has been shown to 
prolong the duration of surgical anaesthesia produced by local anesthetic agents and extend 
the postoperative analgesia beyond the period of anaesthesia. At spinal level, its analgesic 
effect is believed to be mediated by postsynaptically situated alpha-2 adrenoreceptors in the 
dorsal hom. This mechanism is separate from that of local anaesthetic. In addition, it may 
also have a direct effect on neural transmission (Bernadette Th et al. 1998). Premedication 
with oral clonidine does prolong sensory and motor block from spinal anesthesia with 
tetracaine, lidocaine, and bupivacaine (Bernadette Th et al. 1998). 
The prolongation of local anaesthetic block is more pronounced with 150J.1g clonidine, than 
with 200J.1g epinephrine. Addition of 150 Jlg clonidine to spinal injection does not increase 
the incidence of hypotension associated with spinal anaesthesia; a dose of 200-400 Jlg may 
cause cardiovascular depression (Bernadette Th et al. 1998). 
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2.3. PHYSIOLOGY OF SPINAL ANESTHESIA 
A thorough understanding of the physiology of spinal anaesthesia is essential for its safe 
and effective administration. The degree to which these physiological effects impact on the 
surgical patient and lead to adverse outcomes is dependent on patient co-morbidity, surgical 
operation, clinical setting (inpatient versus ambulatory) and spinal anaesthetic technique. 
Awareness of, and attention to, the factors that potentially cause these physiological effects 
to become complications is important to ensure proper patient selection and preparation 
prior to induction of anaesthesia. 
2.3.1 CENTRAL NERVOUS SYSTEM PHYSIOLOGY 
It is often assumed that local anaesthetics act where they bind with greatest avidity: 
superficial layer of the spinal cord and the dorsal root. Nevertheless, the sites of greatest 
local anaesthesia binding change over time, during which the only obvious change in the 
quality or extent of spinal anaesthesia may be a 1 or 2 spinal segment change in the most 
rostral extent of block. This argues against our attaching great significance to the 
macroscopic extent of local anaesthesia binding in the spinal cord (Butterworth J 1998). It 
is generally assumed that inhibition of nerve conduction during spinal anaesthesia will only 
occur when local anaesthetic concentration exceeds some minimal blocking concentration. 
Differences among neurons in local anaesthetic susceptibility could explain the differential 
block seen in the more rostral spinal segments of a spinal anaesthesia. During clinical 
spinal anaesthesia, kinesthetic sensibility is often inhibited in more rostral dermatomes than 
light touch, which in tum is inhibited in more rostral dermatomes than pinprick sensibility. 
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The classic data, reported by Greene in 1958, demonstrated that there was typically a 2 
spinal- segment separation between the more rostral inhibition of cold sensation and that of 
pinprick anaesthesia. Freund et al 1967 used electromyography techniques to compare the 
rostral extent of motor and sensory block, showing a median 2.5 segment differential 
between the two. Finally, Chamberlain used thermograph during lidocaine or tetracaine 
spinal anaesthesia to define a wide margin of differential block between sympathetic and 
somatic sensory fibers. These authors found a mean 6-7 segments between the rostral 
margins of the two modalities (Butterworth J 1998) 
2.3.2 CARDIOVASCULAR PHYSIOLOGY 
The cardiovascular effects of spinal anaesthesia depend primarily on the rostral extent of 
sympathetic block and secondarily on the degree of sedation. Hypotension and bradycardia 
are both well-recognized side-effects of spinal anaesthesia, although their clinical 
presentations are usually mild and respond rapidly to treatment. However, a systole and 
cardiac arrest can occur suddenly and may lead to significant morbidity or even mortality. 
2.3.2, (a). Hypotension 
The underlying mechanisms of spinal anaesthesia- induced hypotension have been studied 
both in animals and in patients. Butterworth et al. used a canine model with 
cardiopulmonary bypass to separate spinal anaesthesia effects on the arterial and venous 
circulations from those on the heart. Decreases in the blood volume contained by the 
venous reservoir (of the bypass circuit) denoted increases in venous capacitance. 
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